TrialBMC cancer2022

Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.

Zhichao Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.